MIRATI THERAPEUTICS INC (MRTX) Fundamental Analysis & Valuation

NASDAQ:MRTX • US60468T1051

Current stock price

58.7 USD
-0.1 (-0.17%)
At close:
58.99 USD
+0.29 (+0.49%)
After Hours:

This MRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MRTX Profitability Analysis

1.1 Basic Checks

  • In the past year MRTX has reported negative net income.
  • MRTX had a negative operating cash flow in the past year.
MRTX Yearly Net Income VS EBIT VS OCF VS FCFMRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -200M -400M -600M

1.2 Ratios

  • MRTX has a Return On Assets of -64.25%. This is in the lower half of the industry: MRTX underperforms 64.25% of its industry peers.
  • MRTX has a Return On Equity (-76.69%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.25%
ROE -76.69%
ROIC N/A
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRTX Yearly ROA, ROE, ROICMRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

  • MRTX has a Gross Margin of 88.50%. This is amongst the best in the industry. MRTX outperforms 90.56% of its industry peers.
  • MRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRTX Yearly Profit, Operating, Gross MarginsMRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MRTX Health Analysis

2.1 Basic Checks

  • MRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MRTX has been increased compared to 1 year ago.
  • MRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRTX Yearly Shares OutstandingMRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
MRTX Yearly Total Debt VS Total AssetsMRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 8.55 indicates that MRTX is not in any danger for bankruptcy at the moment.
  • MRTX's Altman-Z score of 8.55 is amongst the best of the industry. MRTX outperforms 83.64% of its industry peers.
  • MRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.55
ROIC/WACCN/A
WACC10.5%
MRTX Yearly LT Debt VS Equity VS FCFMRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 7.54 indicates that MRTX has no problem at all paying its short term obligations.
  • MRTX's Current ratio of 7.54 is fine compared to the rest of the industry. MRTX outperforms 67.79% of its industry peers.
  • A Quick Ratio of 7.39 indicates that MRTX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.39, MRTX is doing good in the industry, outperforming 67.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.39
MRTX Yearly Current Assets VS Current LiabilitesMRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MRTX Growth Analysis

3.1 Past

  • MRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.74%, which is quite good.
  • Looking at the last year, MRTX shows a very strong growth in Revenue. The Revenue has grown by 223.64%.
  • MRTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.01% yearly.
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%

3.2 Future

  • Based on estimates for the next years, MRTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.99% on average per year.
  • MRTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.18% yearly.
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRTX Yearly Revenue VS EstimatesMRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
MRTX Yearly EPS VS EstimatesMRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRTX Price Earnings VS Forward Price EarningsMRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRTX Per share dataMRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MRTX's earnings are expected to grow with 12.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y12.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRTX Dividend Analysis

5.1 Amount

  • MRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MRTX Fundamentals: All Metrics, Ratios and Statistics

MIRATI THERAPEUTICS INC

NASDAQ:MRTX (1/22/2024, 8:00:02 PM)

After market: 58.99 +0.29 (+0.49%)

58.7

-0.1 (-0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners4.62%
Inst Owner Change0%
Ins Owners10.58%
Ins Owner Change0%
Market Cap4.12B
Revenue(TTM)38.19M
Net Income(TTM)-725.88M
Analysts69.09
Price Target62.42 (6.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.01%
Min EPS beat(2)6.02%
Max EPS beat(2)14.01%
EPS beat(4)4
Avg EPS beat(4)8.85%
Min EPS beat(4)3.16%
Max EPS beat(4)14.01%
EPS beat(8)7
Avg EPS beat(8)5.22%
EPS beat(12)9
Avg EPS beat(12)3.61%
EPS beat(16)11
Avg EPS beat(16)0.87%
Revenue beat(2)0
Avg Revenue beat(2)-7.1%
Min Revenue beat(2)-13.55%
Max Revenue beat(2)-0.65%
Revenue beat(4)1
Avg Revenue beat(4)-6.74%
Min Revenue beat(4)-59.88%
Max Revenue beat(4)47.11%
Revenue beat(8)4
Avg Revenue beat(8)247.34%
Revenue beat(12)6
Avg Revenue beat(12)238.35%
Revenue beat(16)8
Avg Revenue beat(16)201.02%
PT rev (1m)0.84%
PT rev (3m)12.84%
EPS NQ rev (1m)-0.83%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)0.29%
EPS NY rev (3m)4.82%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)-2.26%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.82
P/FCF N/A
P/OCF N/A
P/B 4.35
P/tB 4.42
EV/EBITDA N/A
EPS(TTM)-12.22
EYN/A
EPS(NY)-9.31
Fwd EYN/A
FCF(TTM)-8.5
FCFYN/A
OCF(TTM)-8.47
OCFYN/A
SpS0.54
BVpS13.49
TBVpS13.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.25%
ROE -76.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.5%
FCFM N/A
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.91%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.39
Altman-Z 8.55
F-Score4
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)466.3%
Cap/Depr(5y)417.11%
Cap/Sales(3y)28.4%
Cap/Sales(5y)26.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
EBIT growth 1Y-2.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.48%
EBIT Next 3Y-11.53%
EBIT Next 5YN/A
FCF growth 1Y-77.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.55%
OCF growth 3YN/A
OCF growth 5YN/A

MIRATI THERAPEUTICS INC / MRTX Fundamental Analysis FAQ

What is the fundamental rating for MRTX stock?

ChartMill assigns a fundamental rating of 4 / 10 to MRTX.


What is the valuation status for MRTX stock?

ChartMill assigns a valuation rating of 0 / 10 to MIRATI THERAPEUTICS INC (MRTX). This can be considered as Overvalued.


Can you provide the profitability details for MIRATI THERAPEUTICS INC?

MIRATI THERAPEUTICS INC (MRTX) has a profitability rating of 1 / 10.